Why Scholar Rock Holding Stock Soared Today
The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.
Source: fool.com
Page 3 - Jay Backstrom News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jay Backstrom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jay Backstrom Today - Breaking & Trending Today
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
Topline data from Phase 3 trial expected in Q4 2024 Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023...
Source: marketscreener.com
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
- Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in...
Source: marketscreener.com
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 - Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure... | May 9, 2023
Source: marketscreener.com
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play
Source: finanznachrichten.de